PMID- 35073914
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1477-3155 (Electronic)
IS  - 1477-3155 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Jan 24
TI  - Engineering of small-molecule lipidic prodrugs as novel nanomedicines for 
      enhanced drug delivery.
PG  - 49
LID - 10.1186/s12951-022-01257-4 [doi]
LID - 49
AB  - A widely established prodrug strategy can effectively optimize the unappealing 
      properties of therapeutic agents in cancer treatment. Among them, lipidic 
      prodrugs extremely uplift the physicochemical properties, site-specificity, and 
      antitumor activities of therapeutic agents while reducing systemic toxicity. 
      Although great perspectives have been summarized in the progress of prodrug-based 
      nanoplatforms, no attention has been paid to emphasizing the rational design of 
      small-molecule lipidic prodrugs (SLPs). With the aim of outlining the prospect of 
      the SLPs approach, the review will first provide an overview of conjugation 
      strategies that are amenable to SLPs fabrication. Then, the rational design of 
      SLPs in response to the physiological barriers of chemotherapeutic agents is 
      highlighted. Finally, their biomedical applications are also emphasized with 
      special functions, followed by a brief introduction of the promising 
      opportunities and potential challenges of SLPs-based drug delivery systems (DDSs) 
      in clinical application.
CI  - (c) 2022. The Author(s).
FAU - Huang, Lingling
AU  - Huang L
AD  - Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, 310009, People's Republic of China.
AD  - Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People's Republic 
      of China.
FAU - Yang, Jianmiao
AU  - Yang J
AD  - Taizhou Hospital of Zhejiang Province, Zhejiang, 317000, Taizhou, People's 
      Republic of China.
FAU - Wang, Tiantian
AU  - Wang T
AD  - Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, 310009, People's Republic of China.
FAU - Gao, Jianqing
AU  - Gao J
AD  - Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People's Republic 
      of China. gaojianqing@zju.edu.cn.
AD  - Cancer Center of Zhejiang University, Zhejiang University, Hangzhou, 310058, 
      People's Republic of China. gaojianqing@zju.edu.cn.
FAU - Xu, Donghang
AU  - Xu D
AD  - Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, 310009, People's Republic of China. 
      xudonghang@zju.edu.cn.
LA  - eng
GR  - LY18H300004/Natural Science Foundation of Zhejiang Province/
GR  - LY15H300001/Natural Science Foundation of Zhejiang Province/
GR  - 2021ZYC-Z02/Clinical research project of Zhejiang Medical Association/
PT  - Journal Article
PT  - Review
DEP - 20220124
PL  - England
TA  - J Nanobiotechnology
JT  - Journal of nanobiotechnology
JID - 101152208
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Lipids)
RN  - 0 (Prodrugs)
SB  - IM
MH  - *Antineoplastic Agents/pharmacology/therapeutic use
MH  - Drug Delivery Systems
MH  - Lipids/chemistry
MH  - Nanomedicine
MH  - *Prodrugs/chemistry
PMC - PMC8785568
OTO - NOTNLM
OT  - Cancer
OT  - Drug delivery
OT  - Lipidic prodrug
OT  - Nanomedicine
OT  - Small molecule
COIS- There are no conflicts to declare.
EDAT- 2022/01/26 06:00
MHDA- 2022/04/01 06:00
PMCR- 2022/01/24
CRDT- 2022/01/25 05:37
PHST- 2021/11/12 00:00 [received]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/01/25 05:37 [entrez]
PHST- 2022/01/26 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/01/24 00:00 [pmc-release]
AID - 10.1186/s12951-022-01257-4 [pii]
AID - 1257 [pii]
AID - 10.1186/s12951-022-01257-4 [doi]
PST - epublish
SO  - J Nanobiotechnology. 2022 Jan 24;20(1):49. doi: 10.1186/s12951-022-01257-4.